Fosun Pharma has committed series A funding to Glycotest, a liver disease diagnostics developer based on research at Baruch S. Blumberg Institute and Drexel University.

University of Washington has established RNA sequencing technology developer Split Biosciences, which has raised $1.2m in seed funding from unnamed investors.

Orphan disease drug developer PhaseBio Pharmaceuticals, which is commercialising research from Duke University, cut the price of its shares sharply pre-offering.

Qpex has raised $33m in series A funding from Stanford University Draper Fund and others after spinning out of the Medicines Company to develop drugs targeting superbugs.

Johnson & Johnson was among the investors in a $54.5m series A round for CuraSen Therapeutics, which is commercialising research from Stanford University.

Endocyte emerged out of Purdue University in 1996, completed an initial public offering in 2011 and has now agreed to an acquisition by Novartis worth $2.1bn.

University of Washington’s CoMotion has formed a fintech incubator with nonprofit credit union Becu called the Becu Fintech Incubator.

Occupational learning tool developer NovoEd, based on research at Stanford, has been bought by Devonshire Investors after raising $4.8m of series A capital in 2014.

The cell biology technology developer, based on UC Berkeley research, took its total funding to almost $220m in a Nikon-led round that included fellow strategic backer Varian.

University of Bristol Enterprise Fund II has backed antibiotic diagnostics developer Vitamica, which spun out of the university’s school of physics in January 2018.